Pharmacokinetics of A40926 in rats after single intravenous and subcutaneous doses.

AUTOR(ES)

Bernareggi, A

RESUMO

A40926 is a new glycopeptide antibiotic with unique activity against Neisseria gonorrhoeae and high and prolonged levels in mouse blood (B. P. Goldstein, E. Selva, L. Gastaldo, M. Berti, R. Pallanza, F. Ripamonti, P. Ferrari, M. Denaro, V. Arioli, and G. Cassani, Antimicrob. Agents Chemother., 31:1961-1966, 1987). We studied the pharmacokinetics of A40926 in rats after single intravenous and subcutaneous 10-mg/kg (body weight) doses. Concentrations in plasma and urine were determined by microbiological assay. After intravenous administration, high concentrations of A40926, ranging from 132 mg/liter at 3 min to 0.7 mg/liter at 96 h, were found in plasma. Concentrations declined with a three-exponential decay correlated with a prolonged, biphasic distribution and a slow elimination (terminal half-life, 61.22 h). After completion of the distribution, the compound was widely distributed to the extravascular space. The rate-limiting step in the elimination of A40926 from the body appears to be the slow return from the deep compartment into the central one. A40926 was rapidly absorbed from the injection site after subcutaneous administration, and its availability was close to 90%. The percentage of the dose excreted in urine in 120 h was 35.9%.

Documentos Relacionados

• Rimantadine pharmacokinetics after single and multiple doses.
• Pharmacokinetics of temafloxacin in humans after single oral doses.
• Difloxacin metabolism and pharmacokinetics in humans after single oral doses.
• Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses.
• Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses.